Open access
A Real‐World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B‐Cell Lymphoma
L. Budde
A. Olszewski
Bei Hu
Nikesh N. Shah
C. Batlevi
S. Yin
I. To
Michael C. Wei
M. Kallemeijn
L. Musick
L. Lundberg
Natasha Shamas
M. Dixon
N. Pal
A. Shewade
J. Westin
Medicine
Abstract
Data for the use of rituximab, gemcitabine, and oxaliplatin (R‐GemOx) for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) in the United States are limited. This retrospective observational study characterizes R‐GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron Health electronic health record‐derived database comprising patient‐level data primarily from US community oncology practices.